In a report released today, Gena Wang from Barclays maintained a Hold rating on PTC Therapeutics (PTCT – Research Report), with a price target of $25.00. The company’s shares closed yesterday at $28.19.
According to TipRanks, Wang is a 5-star analyst with an average return of 11.0% and a 47.52% success rate. Wang covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Sarepta Therapeutics, and BioCryst.
PTC Therapeutics has an analyst consensus of Hold, with a price target consensus of $26.67, implying a -5.39% downside from current levels. In a report released yesterday, TD Cowen also maintained a Hold rating on the stock with a $30.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $59.84 and a one-year low of $17.53. Currently, PTC Therapeutics has an average volume of 1.1M.
Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PTCT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PTC Therapeutics (PTCT) Company Description:
PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically-differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The company was founded by Allan Steven Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.
Read More on PTCT:
- PTC Therapeutics Q4 and Fiscal Year-End Financial Update Call
- PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
- SHAREHOLDER ALERT: Potential Recovery for PTC Therapeutics, Inc. (PTCT) Investors
- PTCT Earnings this Week: How Will it Perform?
- PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
